Newron Pharmaceuticals SpA (NWPHF) Price & Analysis

20 Followers

NWPHF Stock Chart & Stats

$20.00

$0.00(0.00%)

At close: Mar 31 4:00 PM EDT

$20.00

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$9.36 - $20.00

Previous CloseN/A

Volume125.00

Average Volume (3M)0.00

Market Cap

$203.42M

Enterprise Value$273.34M

Total Cash (Recent Filing)$32.99M

Total Debt (Recent Filing)$39.16M

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Mar 16, 2027

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.46

Shares Outstanding21,238,867

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)-45.95

Price to Sales (P/S)26.73

P/FCF Ratio15.73

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue26.25

Enterprise Value/Gross Profit26.24

Enterprise Value/Ebitda-16.63

Forecast

1Y Price Target

$29.53

Price Target Upside47.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-1.72

Revenue Forecast (FY)$13.40M

Bulls Say, Bears Say

Bulls Say

Strategic Partnership And FundingThe Eisai partnership provides external validation for evenamide while the collected funding and additional financing access support continued clinical development. Deferred EIB repayments also preserve liquidity, giving Newron more time to advance its program before substantial debt service begins.

Large Global Pivotal ProgramA large, global pivotal program can generate meaningful evidence across multiple studies and improve the credibility of a future regulatory submission. Completing these trials would materially advance evenamide from development-stage asset toward potential commercialization and partnering value.

Strengthened Intellectual PropertyAdditional composition-of-matter protection could lengthen the period during which Newron and its partners can commercialize evenamide without direct generic competition. Longer exclusivity may support greater lifetime revenue potential and strengthen the company’s negotiating position with commercial partners.

Bears Say

Elevated Balance-sheet RiskNegative equity and substantial leverage reduce financial flexibility while increasing refinancing and potential dilution risk. These constraints can make it harder for Newron to fund development independently, particularly if clinical milestones or partnering proceeds are delayed.

Volatile And Unprofitable Financial ProfileThe sharp reversal shows that reported revenue and profitability depend heavily on episodic licensing or milestone income rather than a stable commercial base. Recurring losses across much of the longer-term history make durable self-funded growth and predictable earnings difficult to establish.

Clinical Execution And Funding DependenceRecruitment and site-initiation delays could push pivotal readouts beyond planned timelines, extending cash needs and delaying regulatory progress. Because part of the available funding depends on positive results, execution problems or disappointing data could simultaneously pressure both development plans and liquidity.

Newron Pharmaceuticals SpA News

Newron Pharma price target lowered to CHF 30 from CHF 44 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 30 from CHF 44 and...

2d ago

Newron Pharma price target lowered to CHF 19 from CHF 35 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 19 from...

10d ago

Newron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals said the U.S. FDA has issued...

7d ago

Newron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review

An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has received a formal...

7d ago

Newron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals reported that recruitment of new patients...

19d ago

Newron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts

The latest update is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals reported its 2026 half-year...

23d ago

Newron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals reported first-half 2026 results showing a...

23d ago

Newron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an update. Newron Pharmaceuticals has secured a second tranche of...

1M ago

Newron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an announcement. Newron Pharmaceuticals, a neuroscience-focused biopharmaceutical group based near...

1M ago

Newron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia

The latest announcement is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals has completed screening for...

1M ago

Newron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide

An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has completed screening for...

1M ago

Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an update. Newron Pharmaceuticals has provided an update after a...

3M ago

Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and...

5M ago

Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from...

7M ago

NWPHF FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?

Newron Pharmaceuticals SpA lowest stock price was $9.36 and its highest was $20.00 in the past 12 months.

What is Newron Pharmaceuticals SpA’s market cap?

Newron Pharmaceuticals SpA’s market cap is $203.42M.

When is Newron Pharmaceuticals SpA’s upcoming earnings report date?

Newron Pharmaceuticals SpA’s upcoming earnings report date is Mar 16, 2027 which is in 153 days.

How were Newron Pharmaceuticals SpA’s earnings last quarter?

Newron Pharmaceuticals SpA released its earnings results on Sep 22, 2026. The company reported -$0.897 earnings per share for the quarter, missing the consensus estimate of -$0.213 by -$0.684.

Is Newron Pharmaceuticals SpA overvalued?

According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA does not currently pay dividends.

What is Newron Pharmaceuticals SpA’s EPS estimate?

Newron Pharmaceuticals SpA’s EPS estimate is -0.86.

How many shares outstanding does Newron Pharmaceuticals SpA have?

Newron Pharmaceuticals SpA has 21,238,867 shares outstanding.

What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?

Newron Pharmaceuticals SpA reported an EPS of -$0.897 in its last earnings report, missing expectations of -$0.213. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?

Currently, no hedge funds are holding shares in NWPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Newron Pharmaceuticals SpA

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.

Newron Pharmaceuticals SpA (NWPHF) Earnings & Revenues

Historic Earnings Reports

NWPHF Stock 12 Month Forecast

Average Price Target

$29.53

▲(47.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","37":"$37","15.25":"$15.25","22.5":"$22.5","29.75":"$29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.16485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.5346275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.904405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.25,22.5,29.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.24345,22.4869,23.73035,24.9738,26.21725,27.460700000000003,28.704150000000002,29.9476,31.19105,32.4345,33.67795,34.921400000000006,{"y":36.16485,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,20.733432884615386,21.46686576923077,22.200298653846154,22.933731538461537,23.667164423076922,24.40059730769231,25.13403019230769,25.867463076923077,26.600895961538463,27.334328846153845,28.06776173076923,28.801194615384617,{"y":29.5346275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,20.22341576923077,20.446831538461538,20.670247307692307,20.893663076923076,21.117078846153845,21.340494615384614,21.563910384615387,21.787326153846156,22.010741923076925,22.234157692307694,22.457573461538463,22.68098923076923,{"y":22.904405,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >